Immix Biopharma (IMMX) investor relations material

Executive summary

• Focused on developing CAR-T cell therapies, with lead candidate NXC-201 in Phase 1b/2 trials for AL Amyloidosis and other serious diseases.

• NXC-201 received FDA Breakthrough Therapy, RMAT, and Orphan Drug Designations in AL Amyloidosis.

• Positive interim Phase 2 data presented in December 2025; 75% complete response rate observed.

• Company operates as a single segment and continues to incur significant R&D and operating losses.

Financial highlights

• Net loss for Q1 2026 was $10.1 million, up from $4.5 million in Q1 2025, driven by higher R&D and G&A expenses.

• R&D expenses rose to $6.0 million from $2.0 million year-over-year, reflecting increased clinical trial activity.

• G&A expenses increased to $4.8 million from $2.7 million, mainly due to higher compensation and professional fees.

• Interest income grew to $0.7 million from $0.15 million, reflecting higher cash balances.

• Cash, cash equivalents, and short-term investments totaled $90.6 million as of March 31, 2026.

Outlook and guidance

• Cash and investments expected to fund operations for at least 12 months from the filing date.

• Additional capital will be needed beyond this period to continue planned operations and clinical development.

• Ongoing expansion of clinical programs and R&D expected to increase expenses.